{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=47", "query": { "condition": "Follicular Neoplasm", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 1364, "total_pages": 137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T13:58:23.278Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02454270", "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Precursor Cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "Part 1 (Dose Escalation): Duvortuxizumab", "type": "DRUG" }, { "name": "Part 2 (Dose Expansion): Duvortuxizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-06-15", "completion_date": "2018-07-26", "has_results": false, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 6, "location_summary": "Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02454270" }, { "nct_id": "NCT05919069", "title": "A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "AZD2693", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 35, "start_date": "2023-06-16", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 3, "location_summary": "Rialto, California • Miami Lakes, Florida • Orlando, Florida", "locations": [ { "city": "Rialto", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05919069" }, { "nct_id": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-05-11", "completion_date": "2022-08-21", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02733042" }, { "nct_id": "NCT00487513", "title": "Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Procurement of Follicular B Cell Lymphoma Cells", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 40, "start_date": "2007-06", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487513" }, { "nct_id": "NCT00014560", "title": "Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "bispecific antibody 4G7xH22", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2000-09-28", "completion_date": "2003-02-14", "has_results": true, "last_update_posted_date": "2018-05-03", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014560" }, { "nct_id": "NCT06495190", "title": "Cognition, Flavonoids, Exercise, Gut Microbiome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cognitive Decline, Mild" ], "interventions": [ { "name": "Blueberry", "type": "DIETARY_SUPPLEMENT" }, { "name": "Walking", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Stretching", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "BEHAVIORAL" ], "sponsor": "Appalachian State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "65 Years to 85 Years" }, "enrollment_count": 240, "start_date": "2025-01-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 1, "location_summary": "Kannapolis, North Carolina", "locations": [ { "city": "Kannapolis", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06495190" }, { "nct_id": "NCT00082654", "title": "Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Neuroblastoma", "Ovarian Cancer", "Psychosocial Effects of Cancer and Its Treatment", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "psychosocial assessment and care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2002-03", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082654" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT07559474", "title": "A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Insufficiency", "Liver Diseases" ], "interventions": [ { "name": "INCB123667", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2026-05-27", "completion_date": "2027-04-13", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 4, "location_summary": "Chandler, Arizona • Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07559474" }, { "nct_id": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Mediastinal Large B-cell Lymphoma", "Grey Zone Lymphoma", "High Grade B Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Brentuximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12-16", "completion_date": "2017-05-17", "has_results": false, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-11-02T13:58:23.278Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02623920" } ] }